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Context: Atypical femur fractures (AFFs) are serious adverse events associated with 
bisphosphonates and often show poor healing.
Evidence acquisition: We performed a systematic review to evaluate effects of teriparatide, 
raloxifene, and denosumab on healing and occurrence of AFF.
Evidence synthesis: We retrieved 910 references and reviewed 67 papers, including 31 case 
reports, 9 retrospective and 3 prospective studies on teriparatide. There were no RCTs. We 
pooled data on fracture union (n = 98 AFFs on teriparatide) and found that radiological healing 
occurred within 6 months of teriparatide in 13 of 30 (43%) conservatively managed incomplete 
AFFs, 9 of 10 (90%) incomplete AFFs with surgical intervention, and 44 of 58 (75%) complete 
AFFs. In 9 of 30 (30%) nonoperated incomplete AFFs, no union was achieved after 12 months and 
4 (13%) fractures became complete on teriparatide. Eight patients had new AFFs during or after 
teriparatide. AFF on denosumab was reported in 22 patients, including 11 patients treated for 
bone metastases and 8 without bisphosphonate exposure. Denosumab after AFF was associated 
with recurrent incomplete AFFs in 1 patient and 2 patients of contralateral complete AFF. Eight 
patients had used raloxifene before AFF occurred, including 1 bisphosphonate-naïve patient.
Conclusions: There is no evidence-based indication in patients with AFF for teriparatide apart 
from reducing the risk of typical fragility fractures, although observational data suggest that 
teriparatide might result in faster healing of surgically treated AFFs. Awaiting further evidence, 
we formulate recommendations for treatment after an AFF based on expert opinion. (J Clin 
Endocrinol Metab 105: 1682–1699, 2020)
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Antiresorptive drugs such as bisphosphonates are widely used for the treatment of osteoporosis. 
Although effective for prevention of osteoporotic frac-
tures, use of bisphosphonates is associated with rare but 
serious adverse events such as osteonecrosis of the jaw 
and atypical femur fractures (AFFs). An AFF is a spon-
taneous or low-trauma, subtrochanteric or femur shaft 
fracture often complicated by delayed or nonunion 
(26%–39%) and bilateral occurrence (2, 3).
The age-adjusted incidence rate of AFF has been esti-
mated to be 1.8 per 100 0000 person-years in patients 
on bisphosphonate use under 2 years, increasing to 113 
per 100 000 person-years with more than 8 years’ dur-
ation (4). It is thought that decreased bone resorption in 
bisphosphonate users results in suppressed bone turn-
over with accumulation of microcracks and homoge-
neously mineralized bone, making the bone more brittle 
and allowing the development of a spontaneous femur 
fracture. However, it is uncertain if bisphosphonates 
are causally related to AFF, and, incidentally, AFFs do 
occur in bisphosphonate-naïve individuals (5). Usually, 
bisphosphonates are discontinued after AFF is diag-
nosed. It has been shown that the risk of AFF decreases 
70% per year from the last use of antiresorptive drugs 
(6), although it is not certain that this risk reduction is 
also seen in patients who have already sustained an AFF.
It is unclear if alternative osteoporosis drugs, par-
ticularly anabolic drugs, can promote AFF healing. 
Moreover, there is no guideline on how patients should 
be treated after an AFF where the risk of causing new 
atypical fractures should be weighed against the risk of 
fragility fractures when not treating osteoporosis. It has 
been proposed that teriparatide, an analog of parathy-
roid hormone, is a safe option for treatment of osteo-
porosis in patients with AFF, especially since it may 
also have a beneficial effect on the healing of AFF it-
self (7). Teriparatide is the only anabolic osteoporosis 
drug that is currently globally available. It directly 
stimulates osteoblasts that might enable the formation 
of new, heterogeneously mineralized bone at the frac-
ture site of AFF. Besides teriparatide, antiresorptive 
drugs, other than bisphosphonates, such as raloxifene 
and denosumab may be considered for osteoporosis 
treatment in patients with AFF. Denosumab is a human 
monoclonal antibody to RANKL and a potent inhibitor 
of bone resorption. Although AFFs have been reported 
in patients exposed to denosumab in case reports, it 
has not been clearly established in epidemiological 
studies how often denosumab, with or without pre-
ceding bisphosphonate use, is associated with AFF. The 
radiological healing or deterioration of AFF while on 
denosumab treatment is also not known. Raloxifene is a 
selective estrogen receptor modulator (SERM) that acts 
as an estrogen agonist in bone, with an antiresorptive 
effect that is milder than that of bisphosphonates and 
denosumab. The relationship between raloxifene and 
the occurrence of AFF has not been investigated. To 
our knowledge, this is the first review that explored 
denosumab and raloxifene in addition to teriparatide 
for medical management of osteoporosis in patients 
with AFF. Further, we investigated whether AFF occurs 
as an adverse event in clinical trials with 2 novel drugs 
for osteoporosis, romosozumab and abaloparatide. 
Romosozumab, an antibody to sclerostin with both ana-
bolic and antiresorptive effects, was recently approved 
in Europe, Japan, and the United States for the treat-
ment of (severe) osteoporosis. Abaloparatide is a syn-
thetic analog of parathyroid hormone-related protein. 
Strontium ranelate was not included in this review since 
this drug is no longer available in most countries.
We performed a systematic literature review to assess 
both the occurrence and the radiological healing of AFFs 
in patients who had used or were using teriparatide, 
denosumab, or raloxifene. We formulate recommenda-
tions for healing of the AFF itself and for osteoporosis 
management in patients who have sustained an AFF and 
are at high risk of fragility fractures.
Methods
We performed a search using key words related to AFFs 
and teriparatide, denosumab, and/or raloxifene in Embase, 
Medline Epub (Ovid), Web of Science and Cochrane Central 
on May 28, 2018. We separately searched for AFF as an adverse 
event in clinical trials with romosozumab or abaloparatide. 
Reviews and articles written in a language other than English 
were excluded. Conference abstracts and original research 
articles were included. Articles were reviewed when AFF was 
diagnosed during or after the use of teriparatide, denosumab, 
and raloxifene or when the radiological healing of AFF in a 
specified amount of time was reported using these drugs.
A complete AFF was defined as a noncomminuted 
subtrochanteric or femur shaft fracture with a predominantly 
transverse fracture line that may become oblique as it pro-
gresses medially, after no or minimal trauma. An incomplete 
form of AFF was defined as a localized endosteal or periosteal 
thickening of the lateral cortex of the subtrochanteric femur 
with or without the presence of a lucent line. When the au-
thors did not describe whether a fracture line was visible, we 
assessed medical imaging in the article to review the presence 
of a fracture line.
We extracted data on sex, median age, ethnicity, use of 
bisphosphonates, surgical interventions, and clinical or func-
tional outcome after the AFF as far as this information was 
available.
We assessed the occurrence of newly diagnosed AFF during 
or after the use of teriparatide, denosumab, or raloxifene. 
Newly diagnosed AFF could either be the first clinical 
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presentation of AFF, a second AFF of the contralateral femur, 
or recurrent AFF at the ipsilateral femur.
For the assessment of radiological healing, the results were 
categorized for each type of drug according to study design 
(case report, retrospective cohort, and prospective studies) and 
fracture type (complete AFF, incomplete AFF with or without 
surgical treatment) (Fig. 1).
We assessed the total number of AFFs described in the lit-
erature with complete radiological healing at 6 months and 
12  months after medical management. The number of con-
servatively treated incomplete AFFs that developed a lucent 
line or progressed to complete AFF was also noted. We pooled 
these data on healing from all article types to provide better in-
sight into the effectiveness of the drugs for the healing of AFF.
Radiological healing in complete AFFs and surgically 
treated incomplete AFFs was defined as adequate callus 
bridging. Radiological healing of an incomplete AFF on con-
servative management was defined by disappearance of a vis-
ible fracture line. Radiological healing of incomplete AFFs 
without a lucent line included flattening of cortical thickening, 
disappearance of bone marrow edema on magnetic resonance 
imaging (MRI) scan, or fading of hotspots on bone scintig-
raphy. Incomplete AFFs with localized cortical thickening 
only, without abnormalities on MRI scan or bone scintig-
raphy, were excluded from assessment of radiological healing 
because focal cortical thickening can remain unchanged for 
more than 5 years after diagnosis of incomplete AFF (8). We 
give our recommendations for teriparatide, denosumab, and 
raloxifene in the medical treatment of patients with AFF. In 
order to address the decision-making in individual cases, we 
have formulated treatment advice for patients with a new 
diagnosis of AFF and patients with AFF who have completed 
a 2-year course of teriparatide. These considerations are based 
on the findings in this review and our expert opinion.
Results: Systematic Review
Our search retrieved 910 references. We selected 2 con-
ference abstracts and 130 articles after screening of 
title and abstract. We replaced one conference abstract 
with the article that was published shortly after our 
search date (9, 10). After full-text reading, 67 articles 
were included for this review. Sections on teriparatide, 
denosumab, and raloxifene have overlapping references 
because some case descriptions report on a combination 
of these treatments in patients with AFF.
Teriparatide
We found 31 case reports, 9 retrospective cohort 
studies, and 3 prospective studies that have reported 
the effect of teriparatide on the radiological healing 
of AFF or occurrence of AFF. There were no published 
randomized controlled trials (RCTs). Detailed study 
descriptions of case reports, retrospective cohorts, 
and prospective studies on teriparatide use in pa-
tients with AFF can be found in Supplement 1(1). The 
demographic characteristics of the patients with AFF 
on teriparatide in case reports are stated in Table  1. 
Clinical variables and main findings from retrospective 
cohorts and prospective studies are summarized in 
Table 2 and Table 3, respectively. The pooled data on 
radiological healing of AFF with teriparatide treatment 
are shown in Table 4.
Teriparatide use and occurrence of  AFF. New AFF 
cases during or after teriparatide use were reported in 8 
patients and always occurred in patients with previous 
bisphosphonate exposure. The new AFFs occurred after 
4, 11, 18, and 24 months of teriparatide treatment in 
4 patients (11–14). The remaining 4 patients were de-
scribed in a conference abstract that did not report the 
duration of teriparatide at time of diagnosis, but all 
developed new incomplete AFFs during teriparatide 
Drug
Teriparade
Denosumab
Raloxifene
Design
Case report
Retrospecve 
cohort
Prospecve 
study
Fracture type
Complete AFF Incomplete AFF (conservave)
Incomplete AFF 
(surgical)
Figure 1. The results for each type of drug were categorized according to study design and fracture type. Abbreviation: atypical femur fracture.
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therapy in the same femur in which the first incomplete 
AFF was diagnosed (15).
Six of the 8 patients had been diagnosed with an-
other AFF before, but in 2 patients, the AFFs during 
teriparatide were the first AFFs (12, 13). One patient 
was diagnosed with a complete and contralateral incom-
plete AFF 2  years after stopping teriparatide without 
any antiresorptive use in the meantime, but the patient 
had been treated for 8 years with antiresorptives in the 
past (12).
Teriparatide use after AFF 
Descriptive data of case reports, retrospective and 
prospective studies. In 33 patients, a total of 24 in-
complete AFFs and 27 complete AFFs were reported at 
the time of starting teriparatide treatment in 31 case re-
ports. In 13 (54%) incomplete AFFs, a fracture line was 
described or visible on the images in the publication, 
while the other cases of incomplete AFFs only showed 
focal cortical thickening on x-ray. The majority of cases 
were women (n = 27, 82%). The mean age of all patients 
with AFF was 67 years, ranging from 21 to 84 years. 
Only a minority of studies (39%) reported ethnicity in 
13 patients, of whom 9 were Caucasian. All cases of 
AFF were associated with the use of bisphosphonates. 
A total of 27 (82%) patients were previously exposed to 
alendronate therapy. The mean treatment duration with 
antiresorptive drugs was 8.3 years, with a minimum dur-
ation of 2 years and a maximum exposure of 17 years. 
Three patients were diagnosed before the AFF with 
osteogenesis imperfecta (16–18), and 1 patient was gen-
etically tested after the occurrence of bilateral incom-
plete AFFs that revealed hypophosphatasia (19).
Nine retrospective cohorts that comprised a total of 
201 patients with AFF reported the effect of teriparatide 
use on radiological healing. Five cohorts involved in-
complete forms only (15, 20–23), 3 cohorts described 
complete fractures only (24–26), and 1 cohort was 
mixed (27). Six cohorts consisted of entirely Asian 
populations. In 8 cohorts, all AFF cases were ex-
posed to antiresorptive therapy and 1 cohort had 23% 
bisphosphonate-naïve patients.
Three prospective studies comprised a total of 31 
women and 1 man, with a mean age of 73 years, who 
were treated for bisphosphonate-associated AFFs with 
teriparatide. Only 1 of these studies had controls (n = 9 
patients) without teriparatide treatment (28). All 3 
studies had a mix of complete and incomplete AFFs. 
Teriparatide was started immediately after surgery in 
1 study and compared with delayed commencement 
of teriparatide 6 months postoperatively (29), while in 
the other 2 studies, teriparatide was started between 7 Re
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weeks to just over 1 year after the diagnosis of AFF (28, 
30). The study by Greenspan et al included 4 individ-
uals with periprosthetic fractures (29), which strictly 
does not adhere to the diagnostic criteria for AFF as for-
mulated by the American Society for Bone and Mineral 
Research (3).
Radiological healing of AFF after teriparatide: 
pooled data. We pooled findings on fracture union 
and teriparatide use in case reports and retrospective 
studies. Apart from deterioration of incomplete AFFs to 
complete fractures in 2 patients (30), no data on radio-
logical healing from the 3 prospective studies could be 
used for this analysis because either the fracture type 
(28) or time to healing (29, 30) could not be established 
from these publications.
Data on fracture healing of 165 AFFs in 140 patients 
were pooled in Table  4, of which 96% were women 
(11, 14, 16–18, 21–27, 30–49). Teriparatide treatment 
was given for 98 (59%) AFFs while 67 AFFs from con-
trol groups in the cohort studies (all complete AFFs) 
did not receive teriparatide. The number of incomplete 
nonoperated AFFs without teriparatide was too small for 
comparison (n = 4), and there were no controls for sur-
gically managed incomplete AFF. Healing of the fracture 
was achieved within 6 months of starting teriparatide in 
13 (43%) incomplete nonoperated AFFs, 9 (90%) sur-
gically treated incomplete AFFs, and 44 (76%) complete 
AFFs. In the non-teriparatide-treated group, 34 (51%) 
complete AFFs healed within 6 months. Complete AFFs 
appeared to heal faster with teriparatide compared 
with controls without teriparatide, but in both groups, 
nonhealing occurred at 12  months postoperatively 
in a small portion of patients: 5 (9%) AFFs in the 
teriparatide users; and 4 (6%) AFFs in those without 
teriparatide. Teriparatide was started in 11 patients be-
cause of signs of delayed healing or nonunion, ranging 
from 2 months to 2 years after the initial diagnosis of 
AFF (n = 2 incomplete, conservatively managed AFFs; 
n = 9 complete AFFs) (14, 17, 18, 26, 31, 34, 36, 39, 
41, 42, 44). Sixteen patients with 18 fractures had not 
discontinued bisphosphonates immediately after the 
diagnosis of AFF, ranging from 3 weeks up to 1 year, 
including 4 AFFs in 4 patients in the teriparatide-treated 
group (n = 2 incomplete, conservatively managed AFFs; 
n = 2 complete AFFs) and 12 controls with 14 complete 
AFFs (24, 25, 30, 31, 45). Progression from incomplete 
to complete AFFs occurred in 4 patients after initiation 
of teriparatide at varying intervals: 9 days, 2 months, 
8 months, and 21 months (23, 30, 48).
Denosumab
Denosumab use and occurrence of AFF. A total 
of 31 AFFs in 22 patients were reported after the use 
of denosumab in 14 case reports and 2 clinical trials. 
The characteristics of these patients are summarized 
in Table 5. Ethnicity was stated only in 3 reports, with 
subjects of a Caucasian (n  =  1) or Japanese (n  =  4) 
background (50–52). Eleven patients with 15 AFFs 
were treated for osteoporosis with denosumab 60 mg 
half-yearly (43, 52–60), while 16 AFFs in 11 patients 
have been reported after denosumab treatment with 
a high dose of 120  mg monthly for metastatic bone 
disease (50, 51, 61–64).
AFF occurred in 8 patients without prior 
bisphosphonate use (9, 52, 59–61, 63, 64), of which 
4 were in patients treated in an oncology setting (61, 
63, 64), meaning that only 4 cases were documented of 
Table 4. Radiological Healing of AFF After Teriparatide: Pooled Data
Fracture Healing and Teriparatide Use;  
n = 140 Patients
Incomplete AFF 
(conservative)
Incomplete AFF 
(surgical) Complete AFF
TPT TPT TPT No TPT
 Number of AFFs (total 165) 30 10 58 67
Healing ≤ 6 months of TPT 13 (43%) 9 (90%) 44 (76%) 34 (51%)
Healing 6–12 months of TPT 4 (13%) 1 (10%) 9 (16%) 29 (43%)
No union achieved at 12 months 9 (30%) - 5 (9%) 4 (6%)
Progression to complete AFF 4 (13%) NA NA NA
Abbreviations: AFF, atypical femur fracture; NA, not applicable; TPT, teriparatide.
Five AFFs that underwent surgical procedures from Takakubo et  al were categorized as complete fractures. In the study by Miyakoshi et  al, 1 
nonoperated incomplete AFF and 1 surgically treated incomplete AFF on teriparatide and 8 complete AFFs without teriparatide were labeled as 
healed by the authors between 6 and 24 months. These fractures were categorized as “healing at 12 months.” From the study by Sato et al, only 
progression to complete AFF in 1 patient on teriparatide and 1 without teriparatide could be established, while for the other 19 incomplete AFFs, 
the fracture healing was not specified.
Included articles: (10, 13, 15–17, 20–26, 29–38, 40–49)
Excluded: Patients (n = 7) without fracture consolidation after ≤ 6 months of teriparatide use (18, 50, 51) (n = 3), (20) (n = 3 with surgery after 
3 months), (48) (n = 1, case no. 3), fracture healing could not be assessed with certainty (52, 53), duration of fracture healing or fracture type were 
not reported (14, 19, 27, 28).
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AFF after use of denosumab for management of osteo-
porosis (9, 52, 59, 60). Two bisphosphonate-naïve indi-
viduals developed an AFF following the sixth and the 
fourteenth dose of denosumab in the FREEDOM-trial, 
a phase 3 clinical trial with denosumab in 4550 women 
with osteoporosis (59, 60). The first patient stopped 
denosumab and achieved fracture healing within 
6  months, while the latter continued denosumab, but 
no data on the healing of AFF are available in this case 
(personal communication by Amgen, October 2018). 
One 60-year-old male who had been on glucocorticoids 
for asthma for more than 30 years developed an AFF 
without any previous bisphosphonate use 2  months 
after the second dose of denosumab, which was given 
in a RCT of denosumab in patients with glucocorticoid-
induced osteoporosis (9). The fourth case without 
bisphosphonate exposure concerns an incomplete, medi-
ally located AFF after only 1 injection of denosumab 
and without abnormalities on x-ray but with periosteal 
reaction on the MRI scan (52). Although stress fractures 
resembling AFF located on the medial instead of the 
lateral cortex have been described (65), this case does 
not meet the diagnostic criteria of AFF according to the 
American Society for Bone and Mineral Research Task 
Force (3). The 4 bisphosphonate-naïve AFF cases treated 
for metastatic bone disease occurred after 21, 24, or 42 
doses of 120 mg denosumab monthly (61, 63, 64). In 
2 other cases, the influence of bisphosphonates on the 
risk of AFF cannot be excluded, but AFF was preceded 
by very short bisphosphonate treatment before starting 
denosumab (53, 55). These 2 cases are very similar, since 
both patients had used alendronate for just a few weeks 
before switching to strontium ranelate because of side 
effects, which was subsequently replaced by denosumab, 
again because of intolerance to the drug. Both patients 
developed an AFF after 3 doses of denosumab (53, 55). 
These reports of AFF after denosumab with minimal or 
no previous bisphosphonate use are suggestive of a role 
for denosumab in the development of AFF, but the num-
bers are small, and AFFs have also been reported rarely 
in patients never treated for osteoporosis (5, 66, 67). In 
another report, the AFF appeared to be triggered by 1 
dose of denosumab in December 2012 after 5years of 
alendronate use between 1994 and 1999 (57), followed 
by a subsequent drug holiday for 13 years.
Denosumab use after AFF
We found 7 papers that reported on the use of 
denosumab after an AFF in 10 patients (18, 45, 58, 
68–71).
Bisphosphonates switched to denosumab treat-
ment. Seven patients switched from bisphosphonates 
to denosumab just before or after the first AFF. 
One patient with an incomplete AFF after 4  years of 
risedronate who underwent preventive placement of an 
intramedullary gamma nail was switched to denosumab 
and had delayed healing after 6 and 12  months (68). 
In a case series of complete AFFs associated with 
alendronate use (69), 4 patients started denosumab 
after the first AFF. There were 4 different outcomes. One 
patient had delayed fracture healing at 12 months but 
with minimal pain and almost the same activity level. 
One patient had a second complete AFF on the contra-
lateral side 1  year after switching to denosumab; this 
contralateral AFF showed bridging callus formation at 
9 months’ follow-up. One patient had bridging callus 
formation at 12 months and was pain-free. One patient 
Table 5. Occurrence of AFF During or After the Use of Denosumab
Osteoporosis (n = 11) Bone Metastases (n = 11) Overall (n = 22)
Number of AFFs 15 16 31
Mean age (min-max; years) 70.7 (59–81) 54.7 (50–86) 62.7 (50–86)
Female (%) 10 (91%) 10 (91%) 20 (91%)
Complete AFFs (%) 11 (73%) 6 (38%) 17 (77%)
Incomplete AFFs (%) 4 (27%) 10 (62%) 14 (64%)
BP use 7 (64%) 7 (64%) 14 (64%)
BP-naïve 4 (36%) 4 (36%) 8 (36%)
Mean duration of BP, years (range) 9.0 (5 wks–15 yrs) 7.8 (6–11.3) 8.4 (5 wks—15 yrs)
Number of denosumab doses,  
mean (range)
3.2 of 60 mg  
half-yearly (1–14)
30 of 120 mg monthly (18–48) -
Accumulative dose, mg/year 120 1440 -
Number of denosumab doses  
in BP-naïve patients, mean (range)
5.8 (1–14) 29 (21–42) -
Abbreviations: AFF, atypical femur fracture; BP, bisphosphonate. 
Parameters are based on the time of the first AFF. Mean duration of bisphosphonates was calculated in bisphosphonate users only. Incomplete frac-
tures with progression to complete fractures were excluded from the number of incomplete AFFs. Denosumab was dosed 120 mg monthly in onco-
logical patients and 60 mg every 6 months in osteoporosis patients. Missing data: age (n = 2) (63), mean duration of bisphosphonates (n = 3) (55), 
median number of denosumab doses (n = 3) (55). Included articles: (8, 42, 54–68)
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had resumed normal daily activities at 18  months of 
follow-up, and radiographs showed bone healing (69). 
In a case report, 1 patient, who sustained a first com-
plete AFF after 1 dose of denosumab and 8  years of 
alendronate (58), continued denosumab treatment but 
sustained a second complete AFF after 3 more doses of 
denosumab. The authors describe healing of both AFFs 
within 5  months postoperatively. Another case is de-
scribed of denosumab started postoperatively for com-
plete AFF, with full weight-bearing after 3 months and 
no adverse events at 18 months of follow-up; complete 
bony union was achieved at 1 year postoperatively (70).
Teriparatide switched to denosumab treat-
ment. Three cases are reported of denosumab therapy 
following teriparatide. One case involved bilateral in-
complete AFFs without visible fracture lines after 
7 years of oral bisphosphonates and who was treated 
with teriparatide for 18 months and a subsequent drug 
holiday of 12 months (71). The cortical thickening had 
almost completely flattened on x-rays when denosumab 
was prescribed as treatment for low bone mineral 
density (BMD). The authors reported that the patient 
had increasing thigh pain in both upper legs 6 months 
after the first dose of denosumab and that x-rays and 
bone scintigraphy showed recurrent, incomplete bilat-
eral AFFs with presence of a lucent line after which the 
surgeon decided to perform bilateral internal fixation 
(71). Two case reports (1 with incomplete AFF and 
1 with complete AFF) mention that the initiation of 
denosumab therapy had a good outcome in the short 
term (< 1 year) (18, 45).
Raloxifene
Raloxifene use and occurrence of AFF
Six papers (29, 49, 72–75) stated the use of 
raloxifene prior to the diagnosis of AFF in 8 patients, 
although in 4 patients, it was unclear whether this 
was preceded by bisphosphonate treatment (74, 75). 
Two patients had simultaneous use of raloxifene and 
bisphosphonates during 6 months and 6 years, respect-
ively (49, 72). One had had prior bisphosphonate use 
(29). In a case series of surgically treated AFFs from 
Japan (73), a patient treated with raloxifene only was 
reported. This concerned a 77-year-old woman who 
had taken raloxifene and vitamin K2 for only 1 year 
when she sustained an AFF after a fall from standing 
height. Because delayed union was suspected, she re-
ceived low-intensity pulsed ultrasonography 3 months 
postoperatively, and partial fracture healing was seen 
9 months after the surgery (73).
Raloxifene use after AFF
We found reports of 2 patients treated with raloxifene 
after AFF, in both cases after teriparatide treatment (37, 
46). One 63-year-old Asian woman received 10 months 
of teriparatide after incomplete AFF with a visible frac-
ture line, which was subsequently replaced by raloxifene. 
The fracture line had already diminished after 3 months 
of teriparatide and was invisible 15  months after the 
diagnosis, which was 5 months after starting raloxifene 
(37). One 78-year-old woman with incomplete AFF 
with a lucent line received teriparatide; the fracture line 
had almost disappeared 3 months postoperatively. After 
12  months of teriparatide, she switched to a SERM, 
most likely raloxifene, and had an event-free follow-up 
3 years after the diagnosis (46).
Romosozumab
Twelve studies have been performed with romosozumab. 
Two studies reported 3 cases of AFF. One case of AFF 
occurred 3.5 months after the first monthly dose in a 
phase 3 clinical trial (76), but the association between 
romosozumab and the AFF is questionable, given that 
the participant had complained of prodromal pain 
prior to the first romosozumab administration. Two 
cases of AFFs occurred during open-label alendronate 
treatment after 1 year of monthly romosozumab in an-
other trial (77).
Abaloparatide
A total of 9 clinical trials with abaloparatide were pub-
lished. No cases of AFF were reported in patients who 
used or had used abaloparatide.
Discussion
In clinical practice, there is great uncertainty of how to 
treat patients after they have sustained an AFF. This re-
lates both to potential (positive or negative) effects of 
bone agents on the healing of the fracture and to the 
safety of osteoporosis drugs in those patients, who 
are still at high risk of fragility fracture after an AFF. 
Bisphosphonates are usually stopped because patients 
are considered at risk of an AFF of the other femur since 
bilaterality is commonly reported, varying from 28% 
up to 44% (2, 7). In this systematic literature review, we 
aimed to assess the effects of teriparatide, denosumab, 
raloxifene, romosozumab, and abaloparatide on both 
the occurrence and healing of AFF in order to give re-
commendations for medical management. It is difficult 
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to draw firm conclusions because there are no reported 
RCTs of treatment in patients with AFF with any of 
these drugs. Based on descriptions of 165 AFFs treated 
with teriparatide in observational studies, we made a 
crude estimate of effects of teriparatide on radiological 
healing of AFF after 6 and 12 months. The majority of 
surgically treated incomplete (n  =  9, 90%) and com-
plete AFFs (n  =  44, 76%) healed within 6  months of 
teriparatide treatment, in contrast with nonoperated 
incomplete fractures treated with teriparatide (n = 13, 
43%) and complete AFFs that were not treated with 
teriparatide (n = 34, 51%). The reported data are in-
sufficient for an evidence-based recommendation of 
the use of teriparatide to accelerate healing of AFF. Yet, 
keeping in mind the flawed study designs and hetero-
geneity between studies, the observational data might 
suggest that teriparatide could have a beneficial effect 
on the healing time of surgically treated AFF, although 
nonunion after 1 year can still occur. There is no evi-
dence of improved fracture healing for conservatively 
managed incomplete AFFs based on these observational 
data. Our findings clearly show that even during and 
after teriparatide treatment, a new AFF can occur, either 
as a first presentation of AFF or as a second AFF of 
the contralateral femur, but only in patients previously 
treated with bisphosphonates. The role of teriparatide 
for healing of any type of fracture is debated. One meta-
analysis of 5 RCTs in patients with osteoporotic frac-
tures found a significantly shorter healing time in the 
teriparatide-treated group (78), while another analysis 
including also nonosteoporotic fractures did not dem-
onstrate any effectiveness for teriparatide with regard to 
faster union (79). Two RCTs involved subjects with fem-
oral fractures. In one trial with postmenopausal women 
and low-trauma femoral neck fractures, teriparatide 
did not improve radiological fracture healing, but the 
sample size was too small to detect any differences (80). 
The other RCT involved premenopausal women with 
acute stress fractures of the lower extremities and who 
showed a tendency toward improved healing on MRI 
in the teriparatide group (83.3%) in comparison with 
the control group (57.1%), but this was not statistically 
significant (P = 0.18) (81).
There are no documented cases of AFF with the use of 
abaloparatide. This drug might have equivalent effects 
on AFF as teriparatide, given the biological similarity. 
The results from the literature search were insufficient 
to assess the effects on AFF healing by denosumab and 
raloxifene. Despite the lack of epidemiological studies, 
our analysis of the literature suggests that the absolute 
risk of AFF when using denosumab or raloxifene for 
osteoporosis is very low given the limited reports of AFF 
cases using these drugs, 11 and 8 patients respectively, 
and they also mostly occurred after previous use of 
bisphosphonates. However, this risk may be increased 
in patients who have already had an AFF, suggested by 
the reports of 2 patients with a second complete AFF 
(58, 69) on denosumab and in another patient with bi-
lateral recurrent incomplete AFFs on denosumab even 
after use of teriparatide (71). These cases suggest cur-
tailing use of denosumab treatment after an initial uni-
lateral AFF. Romosozumab is linked to 3 AFF cases in 
clinical trials, but it remains to be seen if more cases of 
AFF will develop in patients treated with romosozumab 
with or without bisphosphonate exposure. Based on our 
findings, we conclude that there is a clear need for RCTs 
to evaluate whether teriparatide and/or abaloparatide 
enhances fracture union of AFF (of any type), since this 
is the only drug that is not associated with the devel-
opment of AFF without prior use of bisphosphonates. 
The observational studies in this review are biased and 
lack information on confounding factors such as time 
between diagnosis and starting medical treatment, sur-
gical fixation techniques, smoking, body mass index, 
fracture localization, use of concomitant medication, 
and postoperative weight-bearing protocols. Currently, 
1 clinical trial is ongoing for patients with incomplete 
AFF who are randomized to receive either placebo in-
jections or teriparatide. Changes in pain score and phys-
ical function using the Western Ontario and McMaster 
Universities Osteoarthritis scale and the proportion of 
participants requiring surgery after 12 months serve as 
primary outcomes (82). There are no trials registered 
investigating teriparatide for complete AFF, nonhealing 
AFF, or electively operated incomplete AFF. Also, no 
trials are currently evaluating the risks and benefits of 
antiresorptive therapy compared with placebo in pa-
tients with AFF after stopping teriparatide or in patients 
with AFF managed conservatively or surgically. It is dif-
ficult to set up an adequately powered study because 
of the low incidence of AFF. Therefore, an international 
registry of AFF cases could be very useful to gain insight 
into the safety and efficacy of osteoporosis drugs in re-
lation to fracture healing, bone mineral density, bone 
turnover, and development of new AFFs in these pa-
tients, but this is only possible when patients with AFF 
are referred to specialized centers.
Recommendations for clinical practice 
based on expert opinion
Based on the results in this review and our expert 
opinion, we advise on medical treatment for patients 
with AFF. Our recommendations for medical treatment 
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are summarized in a decision tree (Fig. 2), encompassing 
the occurrence of AFF when using bisphosphonates or 
denosumab and what to do after a patient with AFF has 
completed a 2-year course of teriparatide. In any case, 
extensive monitoring with imaging of both upper legs is 
advised during the first 1 or 2 years after the diagnosis 
of AFF because nonhealing of AFF and contralateral 
AFF may still occur, even on teriparatide.
When AFF is diagnosed during the use of 
bisphosphonates or denosumab, it is recommended 
to stop this treatment since continuation may lead to 
worsening of the AFF or a new contralateral AFF. To 
prevent a rebound effect, discontinuation of denosumab 
could be followed by a short course of bisphosphonates 
or SERMs in patients with surgically treated AFFs. In 
patients at low fracture risk without prevalent vertebral 
fractures who have only had 1 or 2 half-yearly injec-
tions, consider stopping denosumab treatment without 
subsequent therapy. After healing of bilateral, surgically 
managed AFFs, bisphosphonates or denosumab may be 
continued. It should be kept in mind that discontinu-
ation after 3 or more years of bisphosphonate treatment 
may result in increased risk of hip fractures and clinical 
vertebral fractures as shown by some studies (83, 84), 
although this was not found in another recent retro-
spective analysis of a population-based cohort (85). 
Continuation of bisphosphonates might lead to a risk of 
atypical fractures at skeletal sites other than the femur. 
Anecdotally, spontaneous fractures of other long bones 
(eg, ulna, forearm, and tibia) have been reported in rela-
tion to bisphosphonate use (86–93), but no association 
has been established, and the potential risk of such atyp-
ical fractures does not appear to weigh against the risk 
of typical osteoporotic fractures. Teriparatide might be 
started for surgically treated AFFs, although strong evi-
dence for improved fracture union is lacking. Further, 
teriparatide, SERMs, romosozumab, or abaloparatide 
may alternatively be considered in patients at high risk 
of fragility fractures. SERMs are preferably prescribed 
in relatively young, postmenopausal women who are 
Diagnosis of AFF 
Low risk of 
fragility fractures
Risk esmaon for fragility 
fractures
Stop BPs or DMAB
Monitor healing and/or 
development of new AFF with 
imaging of both upper legs 
during 1 to 2 years
High risk of 
fragility 
fracturesa
Unilateral or nonoperated AFF(s)
1. TPT or APT for 2 yearsb
2. If 1 is not an opon, consider:
RMAB
SERMd
HRT or bolonee
Calcitoninf
Bilateral surgically managed AFFs
1.  TPT or APT for 2 yearsb
2. If 1 is not an opon, consider:
Restart DMAB c or BPs 
RMAB
SERMd
HRT or bolonee
Calcitoninf
Nonoperated AFF(s)
Currently no evidence for faster 
AFF healing with TPT 
If ≥2 DMAB injecons, give a short 
course of BPs or SERM d
Surgically managed AFF
No hard evidence, but weak data 
might support faster healing with 
TPTb and might be considered for 3-
6 months depending on availability
If ≥2 DMAB injecons,  consider a 
short course of BPs or SERMd
Aer TPT, consider these opons 
BPs or DMABc if bilateral intramedullary pins
SERMd
RMAB
HRT or bolonee
Calcitonin f
If evidence for very low bone turnover, no follow-up 
therapy might be considered, while monitoring BMD 
and BTM
APT = abaloparade
BMD = bone mineral density
BPs = bisphosphonates
BTM = bone turnover markers
DMAB = denosumab
HRT = hormone replacement therapy
RMAB = romosozumab
SERM = selecve estrogen receptor modulator
TPT = teriparade
Figure 2. Decision tree with considerations for medical management after atypical femur fracture (AFF). aDefinition may vary across countries, eg, 
a hip BMD T-score ≤ –2.5 SD, older age (70–75 years), a recent fragility fracture, other strong risk factors for fracture, or a FRAX fracture risk score 
that is above country-specific thresholds (95). dRaloxifene or bazedoxifene are preferably prescribed in relatively young postmenopausal women 
who are at low risk of hip fractures and deep vein thrombosis (94), or in women in whom the use of teriparatide is contraindicated. eIn case of 
intolerance to SERMs, hormone replacement therapy or tibolone could be considered in women with a low risk of deep vein thrombosis and 
breast cancer, without a history of myocardial infarction or stroke (94). bSwitching denosumab to teriparatide may result in progressive BMD loss. 
cBe aware that antiresorptive therapy may be needed after stopping denosumab. fCalcitonin can be prescribed in patients who are not eligible for 
bisphosphonates, SERMs, hormone replacement therapy, tibolone, abaloparatide, or teriparatide.
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at low risk of hip fractures and deep vein thrombosis 
(94). Hormone replacement therapy or tibolone might 
be considered when SERMs are not tolerated, prefer-
ably in younger women (aged < 65 years) who do not 
have an increased risk of venous thromboembolism and 
are without a history of myocardial infarction or stroke, 
also keeping in mind the increased breast cancer risk 
(94). If the patient is not eligible for any of the aforemen-
tioned drugs, calcitonin can be prescribed as in accord-
ance with the recent guideline of the Endocrine Society 
on pharmacological management of osteoporosis (94). 
The definition of high risk of fragility fractures varies 
across countries, but is often defined by a hip BMD T 
score ≤ –2.5 SD, older age (70–75 years), a recent fra-
gility fracture, other strong risk factors for fracture, or 
a FRAX (https://www.sheffield.ac.uk/FRAX/) fracture 
risk score that is above country-specific thresholds (95).
After 2  years of teriparatide, subsequent therapy 
may be given with raloxifene (or hormone replacement 
therapy) in women and—in those with bilateral surgical 
fixation of AFF—denosumab or bisphosphonates. In 
patients at the end of a (short) course of teriparatide 
who have low bone turnover markers after teriparatide 
or who are deemed to be at low risk of osteoporotic 
fractures, teriparatide may be discontinued without fur-
ther antiresorptive treatment, but close monitoring of 
BMD and bone turnover markers is recommended.
The considerations for each individual drug are given 
in more detail below.
Teriparatide
There is no evidence-based indication for teriparatide 
to enhance healing of AFF, but a tendency toward 
faster healing with teriparatide for surgically managed 
AFFs is seen in the limited, observational data. Hence, 
teriparatide 20 ug daily, when reimbursed, might be 
considered for surgically treated AFF, both incom-
plete AFF and complete AFF. Even during the use of 
teriparatide, nonunions do still occur in surgically man-
aged AFF. The limited data on conservatively managed 
incomplete forms of AFF and use of teriparatide do not 
demonstrate improved fracture healing, but should be 
interpreted with caution, pending the result of an RCT 
that is awaiting results. When teriparatide is given for 
the sole purpose to enhance fracture healing of AFF, a 
short treatment duration of 3 to 6 months may suffice. 
Teriparatide is a reasonable treatment option for pa-
tients who have had an AFF and are still at high risk 
for fragility fractures. A big clinical dilemma is what to 
do after a full 2-year course of teriparatide treatment. 
Normally, antiresorptive therapy is advised after 2 years 
of teriparatide because the positive effects on bone mass 
and strength will in time disappear, as with any drug 
without skeletal retention. Some patients with AFF may 
have inherent low bone turnover, for example, due to an 
underlying monogenetic disease (96) or due to previous 
long-term use of bisphosphonates. It can be speculated 
that accelerated bone loss after cessation of teriparatide 
may not occur in these cases. A few studies describe the 
effect of teriparatide on bone turnover in patients with 
AFF, but the results are inconclusive. Administration of 
teriparatide during 6 months has been associated with a 
significant increase in bone turnover markers in patients 
with AFF (28, 30) and values returned almost to base-
line level after 2 years of teriparatide (30), but pretreat-
ment values varied widely (30, 97) and bone turnover 
markers did not correlate with histomorphometric find-
ings from bone biopsies before and after teriparatide 
treatment in patients with AFF (97). We suggest moni-
toring bone turnover markers on a regular basis in pa-
tients with AFF before, during, and after teriparatide 
treatment and considering antiresorptive drugs when 
levels start to increase or when BMD starts to decrease 
in patients at high risk of fractures. In this situation, 
we suggest either a SERM, romosozumab, calcitonin, 
tibolone, estrogens, denosumab, or bisphosphonates, 
based on sex and on bilaterality of surgical intervention 
(see below).
Denosumab 
When a patient sustains an AFF during the use of 
denosumab, the risk of a rebound effect with rapid 
loss of BMD and potential risk of multiple vertebral 
fractures following cessation of denosumab (98) must 
be weighed against the potentially increased risk of a 
contralateral AFF when continuing denosumab. Patients 
who have already had vertebral fractures appear to be at 
greatest risk of developing multiple vertebral fractures 
after denosumab discontinuation. In general, a course 
of bisphosphonates is recommended after stopping 
denosumab (98). This is not advisable for a conserva-
tively managed incomplete AFF, but a short course of a 
SERM or bisphosphonates may be considered in patients 
with bilateral surgically treated AFFs or a unilateral sur-
gically treated AFF without any radiological signs of in-
complete AFF of the contralateral femur. Denosumab 
could be stopped without follow-up therapy in patients 
at low risk of fragility fractures without prevalent verte-
bral fractures, especially in those who have only had 1 
or 2 half-yearly injections of 60 mg subcutaneously. For 
patients at high risk of fragility fractures, a switch to 
teriparatide or a SERM could be considered. However, 
the rebound effect after stopping denosumab might still 
occur since teriparatide increases bone turnover. One 
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should also be aware of a decrease in BMD, especially 
at cortical sites, as was seen in osteoporotic women who 
transitioned to teriparatide after 2 years of denosumab 
in the DATA-switch study (99). Alternatively, hormone 
replacement therapy or tibolone can be considered in 
women in absence of contraindications such as a high 
risk of breast cancer or deep vein thrombosis, history 
of stroke, or myocardial infarction. Calcitonin is an op-
tion if the patient does not tolerate any of the afore-
mentioned drugs (94). Denosumab could be continued 
or initiated when the patient has bilateral surgically 
treated AFFs and a persistently high risk of fragility 
fractures, including those who have completed 2 years 
of teriparatide. Denosumab therapy for up to 10 years 
has been associated with increasing BMD and low frac-
ture incidence (59). Long-term use of denosumab could 
especially be considered in elderly patients with a life 
expectancy of less than 10  years, for whom this may 
serve as life-long osteoporosis treatment.
Raloxifene
Raloxifene could be considered as follow-up therapy 
after teriparatide when bone turnover markers are high 
in postmenopausal women who do not have a history of 
venous thromboembolic events. Preferably, it is given to 
women who are relatively young and are at lower risk of 
hip fractures. As mentioned above, it could also be con-
sidered in patients who have to stop denosumab because 
they are at risk of another AFF and to potentially pre-
vent the rebound in bone turnover and risk of multiple 
vertebral fractures, especially when they have already 
had vertebral fractures. However, no studies have been 
performed using SERMs to prevent rebound after stop-
ping denosumab. Because it has a weaker antiresorptive 
effect than bisphosphonates or denosumab, and few 
cases of AFF have been reported on raloxifene, this may 
be a preferred option after teriparatide (100, 101). Yet 
it should be kept in mind that raloxifene is not regularly 
prescribed for osteoporosis, hence a low number of AFFs 
associated with raloxifene does not guarantee a lower 
risk of AFF compared with other antiresorptive drugs.
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